Catumaxomab

卡妥索单抗

Report date: 2026/03/19 17:22:50

Base Information

Drug NameCatumaxomab
Drug Alias NameCatumaxomabum卡妥玛索单抗RemovabKorjunyLP000
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > T cell engagers
Mechanisms of ActionAnti-EpCAMAnti-CD3
TargetsEpithelial cell adhesion moleculeT cell surface glycoprotein CD3
Therapy Area/IndicationsAscitesUrinary Bladder NeoplasmsOvarian Neoplasms +[9] 
Global Approved IndicationsAscites
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2009/04/20
Country/TerritoryUnited StatesTaiwanItaly +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNeovii Biotech GmbhTrion Research
China Registration ClassN/A

Develop Information

Active CompaniesLintonpharm Co LtdVetter Pharma-Fertigung Gmbh & Co KgLinton Pacific Ag +[5] 
Inactive CompaniesNeovii Biotech Gmbh
Active IndicationsAscitesUrinary Bladder NeoplasmsStomach Neoplasms
Inactive IndicationsOvarian NeoplasmsColonic NeoplasmsBreast Neoplasms +[6] 

Other Information

ATC CodeL01XC09
Related LinksWikipediaKEGG